Skip to NavigationSkip to content

Antion launch new technology for cancer and tumour treatments

Published on 18/03/21 at 11:34am
researcher in a lab

Antion Biosciences has launched a new T-cell technology platform to help with the development of new curative therapies for diseases with significant unmet need, including a form of blood cancer.

The company’s new miCAR platform has the potential to provide an off-the-shelf treatment option for patients; this is instead of the traditional method for CAR T-cell therapies, which involves extracting the patient’s cells, and longer manufacturing steps.

The miCAR technology will be used primarily to find therapies in multiple myeloma, a cancer of the bone marrow, as well as haematological malignancies and solid tumours. Antion also hopes to use it to target infectious diseases such as HIV and COVID-19.

The miCAR construct is based on Antion’s Therapeutic MiniGene technology, a synthetic microRNA construct which has the ability to accurately silence multiple target genes simultaneously. 

The company were able to create allogeneic miCAR T-cells with the ability to simultaneously silence multiple genes and express therapeutic proteins in a single manufacturing step. These T-cells are designed to overcome the immunosuppressive tumour microenvironment, achieving increased persistence and improved safety.

Dr Sven Kili, CEO of Antion Biosciences, said: “The cell and gene therapy environment is maturing fast and we’ve seen numerous drug approvals over the last few years that have changed the treatment paradigm for patients all over the world. 

“Our miCAR technology builds on the existing work carried out on autologous CAR T-cell therapies and provides patients a much-needed, allogeneic therapy option which will make a positive difference to safety, efficacy and the ease with which patients are treated. 

He continued: “I’m extremely excited to be leading the Antion team as we begin progressing our miCAR T-cell therapy for multiple myeloma, as well as other indications, to the next development stages.”

Jack Goddard

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches